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The glaucoma surgical landscape has changed dramatically over the last decade with the introduction and integration of
micro-invasive glaucoma surgery (MIGS) techniques. These modalities target physiologic outflow pathways or optimize
previously utilized glaucoma surgical methods in order to deliver safety, efficacy, and individualized care to the patient. MIGS
techniques can be classified based on anatomical location as well as method of intraocular pressure (IOP) reduction. This
review will focus on MIGS optimizing the conventional outflow pathway via intervention at Schlemm’s canal, MIGS optimizing
the uveoscleral outflow pathway via suprachoroidal shunting, and MIGS optimizing the transscleral or subconjunctival outflow
pathway which has long been utilized by glaucoma surgeons performing traditional filtration procedures. The wide array of
currently available MIGS modalities can be staggering to the glaucoma care provider, but an understanding of the landscape
and the large classes of interventional strategies can allow for clinical decision making based on the specifics of the patient’s
needs and the pathophysiology of their disease.
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Background
Glaucoma is well recognized as a leading cause of global
vision loss and blindness, with over 100 million people ex-
pected to suffer from the disease by 2040 [1]. Conven-
tional strategies to control glaucoma focus on reduction
of intraocular pressure (IOP). The mainstay of glaucoma
therapy is pharmaceutical, with the utilization of various
classes of topically applied ocular hypotensive agents.
While the number of pharmaceutical agents has steadily
increased over the last several decades, fundamental chal-
lenges to medical therapy continue to exist. Cost, local
and systemic adverse effects, and adherence remain im-
pediments to success with topical medical therapy. Laser
trabeculoplasty has also emerged as a useful adjunct to
conventional medical therapy, and recent studies have
suggested that laser trabeculoplasty may be at least as
effective as medical therapy early in the management of
glaucoma [2]. Unfortunately, the combination of medical
and laser-based therapies may not be enough to control
the IOP of all glaucoma patients. As such, surgical inter-
vention has long been an integral part of the algorithm of
care. The standard surgical paradigm involves bypassing
the eye’s natural aqueous outflow pathways by creating ex-
ternal outflow into the subconjunctival space. The main
methods of doing so are trabeculectomy or the glaucoma
drainage device. Both surgical modalities have demon-
strated efficacy in numerous clinical trials [3]. However,
these surgical strategies carry a significant risk of vision-
threatening morbidity to the patient. In the Primary Tube
Versus Trabeculectomy (PTVT) Study, serious complica-
tions resulting in loss of vision or need for reoperation
occurred in 1% of the drainage device group and 7% of the
trabeculectomy group [3]. While such surgical methods
certainly have their role in the treatment armamentarium,
the relatively high morbidity does not justify their use in
all patients for whom medical and laser-based strategies
have failed.
The era of micro-invasive glaucoma surgery (MIGS),
began as technology evolved, demographic pressures in-
creased, and the glaucoma care community recognized
that a new interventional strategy needed to exist to take
care of patients who required more IOP control than
can be provided by medical and laser-based approaches
but who do not need aggressive surgical intervention.
The traditional tenets of MIGS are that they are deliv-
ered through an ab-interno, micro-incisional approach,
demonstrate moderate efficacy, are minimally traumatic,
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emphasize safety, and ensure a rapid recovery for the pa-
tient [4]. Over the last decade, the MIGS space has
grown tremendously, and has become a major part of
the glaucoma surgical paradigm. Fundamentally, this
growth has enabled glaucoma care providers to provide
more nuanced, patient-centric care.
This review will focus on several of the currently avail-
able MIGS strategies and devices. In order to logically ap-
proach this space, it is important to classify the various
approaches based on the site of anatomical intervention
and augmentation. The rationale for classification is based
on physiological principles that can govern efficacy and
safety of a given family of techniques. As such, this review
will categorize MIGS strategies as Schlemm’s canal MIGS,




The family of micro-invasive strategies directed at
Schlemm’s canal and the conventional outflow system is
likely the richest of the MIGS groups. The pathophysio-
logic rationale for intervening at this anatomical location
lies in bypassing the resistance to aqueous outflow
imparted by the trabecular meshwork tissue. By bypass-
ing such resistance, there exists a theoretical possibility
of achieving an IOP that is similar to the episcleral ven-
ous pressure. Various methods have been developed to
achieve bypass of the trabecular meshwork, namely
microstenting, micro-incisions, and viscodilation.
Microstenting strategies have grown over the last dec-
ade. The original Schlemm’s canal microstent is the first
generation iStent (Glaukos Corp., San Clemente, CA,
USA), which was introduced in the United States in
2012. While the original clinical trials demonstrated
moderate efficacy when these stents were used in com-
bination with cataract extraction [5, 6], their continued
utilization in patients with open angle glaucoma has
consistently demonstrated safety and efficacy. This strat-
egy has led Glaukos to develop a second generation
iStent, known as the iStent Inject [7], which achieved
United States FDA approval in 2018. Additionally, an-
other Schlemm’s canal microstent has been developed
by Ivantis, Inc. (Irvine, CA, USA), called the Hydrus
Microstent [8].
Fundamentally, all three microstents serve to bypass
the resistance of the trabecular meshwork by allowing
aqueous humor to directly flow into Schlemm’s canal.
However, there are subtle differences between the stents
that may be relevant. The original first generation iStent
is a single stent system. However, studies [9] have sug-
gested that multiple stents may achieve greater efficacy
than a single stent. As such, while the iStent Inject is a
smaller individual stent, two stents are included in the
system. The difference in lumen diameter and size is
likely not relevant with regard to the fluid dynamics of
aqueous outflow, but the ability to access a broader area
of the conventional outflow system with a second stent
may be of value. The Hydrus Microstent takes a differ-
ent strategy to broadening the area of coverage; instead
of utilizing multiple stents, the Hydrus Microstent is in
and of itself a longer device. At 8 mm in length, the stent
spans three clock hours of Schlemm’s canal. Addition-
ally, the stent provides both a direct bypass of trabecular
meshwork and a stretching of trabecular meshwork
through its multimodal mechanism of action. In a ran-
domized controlled trial comparing two iStents versus
the Hydrus Microstent, while the IOP results were simi-
lar between the two groups, the Hydrus cohort required
fewer medications and were more likely to be medica-
tion free [10]. Additional comparative studies will ultim-
ately be necessary to further validate these findings, and
it is reassuring that IOP control can safely be achieved
with a variety of microstenting approaches.
Micro-incisional approaches have also grown in popu-
larity over the last several years. Goniotomy and trabecu-
lotomy techniques have long been a mainstay in the
surgical management of pediatric and congenital glau-
comas. In recent years, recognition of the utility of this
surgical approach in adult glaucomas has taken hold. Vari-
ous strategies exist to incise the trabecular meshwork in
order to create a direct pathway for aqueous humor into
Schlemm’s canal and beyond. The Kahook Dual Blade
(New World Medical, Rancho Cucamonga, CA, USA) and
the newer Goniotome (NeoMedix Corp., Tustin, CA,
USA) utilize blades on both sides of a footplate that excise
a bloc of trabecular tissue by making incisions at the an-
terior and posterior margins. Fundamentally, both devices
are simply tools to create this controlled incision, and as
such one would expect similar efficacy between the de-
vices. Numerous reports have shown efficacy similar to
other Schlemm’s canal-based MIGS strategies in patients
with the entire spectrum of disease severity [11, 12]. Fur-
thermore, in the first comparison between modalities,
there was a greater percent reduction in IOP and number
of medications in the goniotomy group as compared to
the iStent group, although both methods resulted in a
similar IOP [13].
As compared to a limited goniotomy using a special-
ized dual blade, in which tissue is excised 180 degrees
from the surgeon, the gonioscopy-assisted transluminal
trabeculotomy (GATT) procedure utilizes either a
microcatheter or a blunted suture to create a circumfer-
ential ab-interno infracture of the trabecular meshwork
[14]. Strengths of this circumferential technique include
the ability to reach all 360 degrees of the distal outflow
system as well as the ability to do so using a potentially
cost-effective method [15]. Longer-term retrospective
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outcome data have documented continued efficacy for
the vast majority of patients [16].
In an effort to be even less injurious to the existing ana-
tomical structures of the anterior chamber angle, viscodi-
lation has been utilized to reduce outflow resistance in the
trabecular meshwork tissue. By distending and enlarging
Schlemm’s canal, adjacent juxtacanalicular trabecular
meshwork and distal collector channels, IOP reduction
can be achieved with minimal disruption. Current
methods to perform viscodilation involve the ab-interno
canaloplasty, or AbIC procedure, as well as the Omni pro-
cedure (Sight Sciences, Inc., Menlo Park, CA, USA). Early
evidence suggests safety and efficacy, again on par with
other Schlemm’s canal techniques [17].
Despite a wealth of strategies to optimize conventional
outflow through the Schlemm’s canal interventional route,
some common points of failure are inevitable. Firstly,
there is a recognition of the fact that wound healing can
occur in this region, which may result in scarring in the
area of microstent implantation or microincision place-
ment. Previous reports have identified scenarios in which
such scarring has resulted in increased IOP and potential
need for additional intervention [18, 19]. Furthermore, pa-
tients with glaucoma may have clinically significant resist-
ance to outflow distal to Schlemm’s canal which may
elevate the floor of IOP reduction after intervention.
There may be a correlation between disease severity and
distal outflow disease, as postulated by Grover et al. and
corroborated by findings of distal outflow sclerosis in
other studies [16, 20, 21]. While continued investigation
and augmentation of technique is inevitable and neces-
sary, the central presence of Schlemm’s canal-based MIGS
in the glaucoma treatment algorithm appears to be
steadfast.
Suprachoroidal MIGS
Just as the Schlemm’s canal-based MIGS aim to aug-
ment the conventional physiologic outflow pathway, the
suprachoroidal MIGS procedures aim to take advantage
of the uveoscleral pathway to reduce IOP. Unlike the
conventional pathway, uveoscleral outflow is not subject
to an IOP floor. As a result, there is theoretically greater
IOP-reducing capacity to this system. The negative pres-
sure gradient of the suprachoroidal space is the driver of
the uveoscleral pathway [22], and surgical device place-
ment to augment this outflow has the potential to con-
vey a substantial IOP reduction.
The first MIGS device to target this space was the
Cypass device (Alcon, Ft. Worth, TX, USA). Early evi-
dence showed significant IOP and medication reduction
for this procedure when combined with cataract extrac-
tion [23]. However, the Cypass device was ultimately
recalled in 2018 when 5-year data suggested a clinically
significantly increased rate of corneal endothelial cell
loss in certain patients with the device. Specifically, pa-
tients in whom the Cypass device was more prominently
positioned in the anterior chamber as opposed to deeper
in the angle and suprachoroidal space exhibited greater
endothelial cell loss. Given that this is a positioning
problem that is potentially addressable, the overall strat-
egy of suprachoroidal stenting is not necessarily
invalidated.
Other devices for augmenting uveoscleral outflow re-
main in development and in the investigational pipeline.
Glaukos Corporation (San Clemente, CA, USA) is ac-
tively investigating the iStent Supra, and iStar Medical
(Wavre, Belgium) is investigating the MINIject device.
The iStent Supra is a small stent 4 mm in length with a
mild curvature to follow the curve of the sclera. In con-
trast, the MINIject is composed of a novel porous sili-
cone material that allows for controlled aqueous outflow
and limited tissue integration.
As this surgical space is relatively sparse, more investi-
gation and clinical data are needed. Nevertheless, there
are potential concerns for failure with this surgical tar-
get. Specifically, wound healing may result in inadequate
IOP reduction. On the other extreme, given the low IOP
floor of the suprachoroidal space, there is the theoretical
risk of clinically significant hypotony, ciliary effusions,
and other choroidal pathology. The unique designs and
material properties of the above mentioned investiga-
tional devices may mitigate some of these risks, and
glaucoma interventionalists hope to have MIGS that ac-
cess the uveoscleral outflow pathway available to them
for certain patients.
Subconjunctival MIGS
In contrast to the MIGS outflow strategies described
above, the subconjunctival route is fundamentally non-
physiologic. Aqueous humor does not naturally flow into
the subconjunctival space, and any attempt to create a
pathway into this space may be met with a scarring re-
sponse. However, the subconjunctival surgical target has
long been a mainstay of conventional glaucoma surgical
intervention, with older surgical modalities like trabecu-
lectomy and glaucoma drainage devices employing this
route. The rationale behind a MIGS approach to this
space primarily focuses on predictability, control, and as
a result, safety. By combining already established know-
ledge regarding subconjunctival and episcleral wound
healing with advancements in device fabrication, the
subconjunctival space offers a powerful pathway for IOP
reduction. Of course, successful subconjunctival outflow
will result in the formation of an aqueous bleb.
The methodology for predictability and control with
subconjunctival MIGS lies in the properties of fluid dy-
namics. As described by Hagen and Poiseuille, resistance
to outflow is proportional to length and radius of the
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path of fluid [24]. Taking advantage of these principles
allows for a device to have an inbuilt outflow resistance
while also allowing early and immediate aqueous flow.
As a result, there is a floor to how low IOP can go, thus
mitigating the risk of hypotony and associated sequelae.
There are currently two devices that take advantage of
these fluid dynamics properties in their design and im-
plementation. The Xen gel stent (Allergan, Inc., Irvine,
CA, USA) has a 45 μm diameter internal lumen and is
delivered using an ab-interno approach through a cor-
neal incision [25]. When the stent emerges in the sub-
conjunctival space, Hagen-Poiseuille’s law predicts a
resistance of approximately 7.5 mmHg, which has been
validated experimentally [24]. Ab-interno deployment of
this microstent essentially eliminates the need for con-
junctival incisions and subsequent closure, and as a re-
sult the risk of wound leakage is essentially absent.
An investigational device that also takes advantage of
the properties of fluid dynamics to achieve flow restric-
tion and increased safety is the Preserflo device (Santen
Co., Japan). While implantation of this microshunt re-
quires an ab-externo delivery via a conjunctival incision
and dissection and a scleral tunnel, a theoretical advan-
tage lies in the design and materials utilized in the de-
vice. Specifically, the Preserflo device is composed of a
material known as SIBS, which has been shown experi-
mentally to be uniquely biocompatible and nonreactive
[26]. As episcleral healing and scarring is a major factor
in subconjunctival surgical failure, any attempt to miti-
gate this reaction may be met with success, although re-
sults from clinical studies of this device are pending to
validate this rationale fully.
Novel surgical targets
The proliferation of MIGS technologies has allowed for
creative approaches to the problem of safe and regulated
IOP control. Innovation and development continue to be
prevalent, and newer MIGS approaches are to be ex-
pected. One example of a unique approach to IOP control
is the Beacon Aqueous Microshunt (MicroOptx, Maple
Grove, MN, USA). The Beacon device is implanted via a
clear corneal incision and allows for aqueous outflow onto
the ocular surface. By using proprietary material property
and nanoscale fabrication techniques, its developers claim
to avoid the risk of pathogen migration into the anterior
chamber. As this strategy is completely novel, it is difficult
to predict potential benefits or challenges that may ac-
company it. Clinical trials of this device are being
designed.
Conclusions
The glaucoma surgical space has grown dramatically, and
interventional strategies and approaches continue to ac-
tively evolve. With so many options available, clinicians
may face a form of choice paralysis in selecting the right
procedure or approach for a given patient. The next phase
in technique evaluation will involve identification of bio-
markers based on patient and disease factors to help tailor
therapy in an individualized manner. Early work has
already begun in this space by recognizing the patho-
physiological basis for certain forms of glaucoma. For ex-
ample, the use of a Schlemm’s canal-based technique has
shown marked efficacy in the treatment of steroid-
induced glaucoma, which is a disease that primarily affects
the trabecular meshwork [27]. Additionally, well-designed
randomized clinical trials will need to be developed to bet-
ter understand the relative strengths and weaknesses of
various MIGS approaches within and across the groups
delineated above.
Ultimately, removing the challenges of medication ad-
herence and placing the control of IOP in the hands of
the glaucoma care provider will be instrumental in ad-
vancing management of this disease. With innovation in
sustained release pharmacotherapy, the possibility of
combined minimally invasive surgical and pharmaceut-
ical intervention by the glaucoma physician is within
grasp. The goal of all physicians should be to prioritize
the patient’s wellbeing and quality of life; the MIGS
revolution has allowed physicians to individualize care
and thereby meet this goal. Continued innovation will
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